Background: Hashimoto’s encephalopathy (HE) presents with a variety of neurologic and neuropsychiatric features. In this study, we investigated the clinical and immunological profiles of the cerebellar ataxic form of HE. Methods: The clinical features, treatments, laboratory features, brain imaging, and serum anti-NH2-terminal of α-enolase autoantibodies (anti-NAE Abs), a useful diagnostic marker for HE, were investigated in 13 patients who presented with sporadic adult-onset cerebellar ataxia and fulfilled the HE diagnostic criteria (antithyroid Abs and responsiveness to immunotherapy). Results: All of the patients presented with truncal ataxia, but nystagmus was uncommon (17%). Eight patients had an insidious onset that mimicked spinocerebellar degeneration (SCD), but brain imaging showed little or no cerebellar atrophy in all of the patients. Those patients with serum anti-NAE Abs (n = 8) did not have nystagmus and tended to respond better to immunotherapy than the anti-NAE Ab-negative patients. Conclusion: The present study suggests that insidious adult-onset and truncal ataxia are common in the cerebellar ataxic form of HE, which mimics SCD, but that nystagmus and severe cerebellar atrophy are uncommon. Antithyroid and anti-NAE Abs may be useful for diagnosing cerebellar ataxic HE.

Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, de Andres C, Maestre J, Fabien N, Vighetto A, Casamitjana R, Thivolet C, Tavolato B, Antoine J, Trouillas P, Graus F: Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies. Study of 14 patients. Arch Neurol 2001;58:225–230.
Bushara KO, Goebel SU, Shill H, Goldfarb LG, Hallett M: Gluten sensitivity in sporadic and hereditary cerebellar ataxia. Ann Neurol 2001;49:540–543.
Hadjivassiliou M, Sanders DS, Woodroofe N, Williamson C, Grünewald RA: Gluten ataxia. Cerebellum 2008;7:494–498.
Bürk K, Wick M, Roth G, Decker P, Voltz R: Antineuronal antibodies in sporadic late-onset cerebellar ataxia. J Neurol 2010;257:59–62.
Fancellu R, Pareyson D, Corsini E, Salsano E, Laurà M, Bernardi G, Antozzi C, Andreetta F, Colecchia M, Di Donato S, Mariotti C: Immunological reactivity against neuronal and non-neuronal antigens in sporadic adult-onset cerebellar ataxia. Eur Neurol 2009;62:356–361.
Rojas I, Graus F, Keime-Guibert F, Reñé R, Delattre JY, Ramón JM, Dalmau J, Posner JB: Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000;55:713–715.
Anderson NE, Rosenblum MK, Posner JB: Paraneoplastic cerebellar degeneration: clinical-immunological correlations. Ann Neurol 1988;24:559–567.
Nakagawa H, Yoneda M, Fujii A, Kinomoto K, Kuriyama M: Hashimoto’s encephalopathy presenting with progressive cerebellar ataxia. J Neurol Neurosurg Psychiatry 2007;78:196–197.
Shaw PJ, Walls TJ, Newman PK, Cleland PG, Cartlidge NE: Hashimoto’s encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers – report of 5 cases. Neurology 1991;41:228–233.
Chaudhuri A, Behan PO: The clinical spectrum, diagnosis, pathogenesis and treatment of Hashimoto’s encephalopathy (recurrent acute disseminated encephalomyelitis). Curr Med Chem 2003;10:1945–1953.
Ferracci F, Bertiato G, Moretto G: Hashimoto’s encephalopathy: epidemiologic data and pathogenetic considerations. J Neurol Sci 2004;217:165–168.
Peschen-Rosin R, Schabet M, Dichgans J: Manifestation of Hashimoto’s encephalopathy years before onset of thyroid disease. Eur Neurol 1999;41:79–84.
Ochi H, Horiuchi I, Araki N, Toda T, Araki T, Sato K, Murai H, Osoegawa M, Yamada T, Okamura K, Ogino T, Mizumoto K, Yamashita H, Saya H, Kira J: Proteomic analysis of human brain identifies alpha-enolase as a novel autoantigen in Hashimoto’s encephalopathy. FEBS Lett 2002;528:197–202.
Oide T, Tokuda T, Yazaki M, Watarai M, Mitsuhashi S, Kaneko K, Hashimoto T, Ohara S, Ikeda S: Anti-neuronal autoantibody in Hashimoto’s encephalopathy: neuropathological, immunohistochemical, and biochemical analysis of two patients. J Neurol Sci 2004;217:7–12.
Gini B, Lovato L, Cianti R, Cecotti L, Marconi S, Anghileri E, Armini A, Moretto G, Bini L, Ferracci F, Bonetti B: Novel autoantigens recognized by CSF IgG from Hashimoto’s encephalitis revealed by a proteomic approach. J Neuroimmunol 2008;196:153–158.
Yoneda M, Fujii A, Ito A, Yokoyama H, Nakagawa H, Kuriyama M: High prevalence of serum autoantibodies against the amino terminal of α-enolase in Hashimoto’s encephalopathy. J Neuroimmunol 2007;185:195–200.
Fujii A, Yoneda M, Ito T, Yamamura O, Satomi S, Higa H, Kimura A, Suzuki M, Yamashita M, Yuasa T, Suzuki H, Kuriyama M: Autoantibodies against the amino terminal of α-enolase are a useful diagnostic marker of Hashimoto’s encephalopathy. J Neuroimmunol 2005;162:130–136.
Manto M, Goldman S, Bodur H: Cerebellar syndrome associated with Hashimoto’s encephalopathy. Rev Neurol (Paris) 1996;152:202–204.
Selim M, Drachman DA: Ataxia associated with Hashimoto’s disease: progressive non-familial adult onset cerebellar degeneration with autoimmune thyroiditis. J Neurol Neurosurg Psychiatry 2001;71:81–87.
Passarella B, Negro C, Nozzoli C, De Marco V, Rini A: Cerebellar subacute syndrome due to corticosteroid-responsive encephalopathy associated with autoimmune thyroiditis (also called ‘Hashimoto’s encephalopathy’). Clin Ter 2005;156:13–17.
Tang Y, Chu C, Lin MT, Wei G, Zhang X, Da Y, Huang H, Jia J: Hashimoto’s encephalopathy mimicking spinocerebellar ataxia. J Neurol 2011;258:1705–1707.
Ferracci F, Moretto G, Candeago RM, Cimini N, Conte F, Gentile M, Papa N, Carnevale A: Antithyroid antibodies in the CSF: their role in the pathogenesis of Hashimoto’s encephalopathy. Neurology 2003;60:712–714.
Etchebehere EC, Cendes F, Lopes-Cendes I, Pereira JA, Lima MC, Sansana CR, Silva CA, Camargo MF, Santos AO, Ramos CD, Camargo EE: Brain single-photon emission computed tomography and magnetic resonance imaging in Machado-Joseph disease. Arch Neurol 2001;58:1257–1263.
Honjo K, Ohshita T, Kawakami H, Naka H, Imon Y, Maruyama H, Mimori Y, Matsumoto M: Quantitative assessment of cerebral blood flow in genetically confirmed spinocerebellar ataxia type 6. Arch Neurol 2004;61:933–937.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.